[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567126":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":33,"locations":41,"responsibleParty":62,"collaborators":30,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":30,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":30,"enrollmentInfo":73,"targetDuration":30,"studyType":76,"phases":77,"briefSummary":69,"conditions":79,"keywords":30,"overallStatus":58,"whyStopped":30,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Jemincare","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"JMKX003002 once daily","EXPERIMENTAL","JMKX003002 once daily for 4 weeks",[13],"Drug: JMKX003002 will be administered orally",{"label":15,"type":10,"description":16,"interventionNames":17},"JMKX003002 twice daily","JMKX003002 twice daily for 4 weeks",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Sevelamer carbonate","ACTIVE_COMPARATOR","Sevelamer carbonate three times daily for 4 weeks",[23],"Drug: Sevelamer carbonate",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","JMKX003002 will be administered orally","tablets for oral administration.",[9,15],null,{"type":26,"name":19,"description":28,"armGroupLabels":32,"otherNames":30},[19],[34,39],{"name":35,"role":36,"phone":37,"phoneExt":30,"email":38},"Jing Xu","CONTACT","0086-020-87755766","xujing2@jemincare.com",{"name":40,"role":36,"phone":37,"phoneExt":30,"email":30},"Wei Chen",[42,57],{"facility":43,"status":44,"city":45,"state":46,"zip":30,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"The First Affiliated Hospital, Sun Yat-sen University","NOT_YET_RECRUITING","Guangzhou","Guangdong","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.25,23.11667,{"lat":53,"lon":52},[56],{"name":35,"role":36,"phone":37,"phoneExt":30,"email":38},{"facility":43,"status":58,"city":45,"state":46,"zip":30,"country":47,"countryCode":48,"cosmosGeoPoint":59,"geoPoint":61,"contacts":30},"RECRUITING",{"type":50,"coordinates":60},[52,53],{"lat":53,"lon":52},{"type":63,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100567126","phase-2-evaluate-the-efficacy-and-safety-of-jmkx003002-in-end-stage-renal-disease-patients-on-hemodialysis-with-hyperphosphatemia-100567126",false,"NCT06664125","Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia","A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia","Inclusion Criteria:\n\n1. Able to understand the procedures of this trial and provide written informed consent voluntarily;\n2. Age ≥ 18 years, male or female;\n3. On a stable hemodialysis regimen at a frequency of two or three times per week for at least 12 weeks prior to the screening visit;\n4. Serum phosphorus within the trial-required range.\n\nExclusion Criteria:\n\n1. Any history of inflammatory bowel disease or diarrheal irritable bowel syndrome;\n2. Pregnant or breastfeeding;\n3. Any history of a parathyroid intervention;\n4. Diarrhea or loose stools occurred within 1 week prior to randomization.","ALL","18 Years",{"count":74,"type":75},50,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2",[80],"Hyperphosphatemia","2025-01-31",{"date":83,"type":84},"2025-02-03","ACTUAL",{"date":86,"type":84},"2024-12-30",{"date":88,"type":75},"2025-09-30",{"name":5,"class":6},2]